Analysts Offer Insights on Healthcare Companies: Biolinerx (NASDAQ: BLRX) and Verona Pharma (NASDAQ: VRNA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biolinerx (BLRXResearch Report) and Verona Pharma (VRNAResearch Report) with bullish sentiments.

Biolinerx (BLRX)

In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Biolinerx, with a price target of $10.00. The company’s shares closed last Tuesday at $6.17.

According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 17.9% and a 42.3% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Global Blood Therapeutics, and Iovance Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biolinerx with a $14.50 average price target, implying a 196.5% upside from current levels. In a report released today, Maxim Group also maintained a Buy rating on the stock with a $10.00 price target.

See today’s analyst top recommended stocks >>

Verona Pharma (VRNA)

Wedbush analyst Liana Moussatos maintained a Buy rating on Verona Pharma today and set a price target of $25.00. The company’s shares closed last Tuesday at $6.41.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.4% and a 43.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Verona Pharma with a $21.50 average price target, which is a 209.8% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $18.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.